Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DW4421-T1 and DW4421S-T1 in Healthy Adults
NCT07364851Phase 1Not yet recruiting
- Sponsor
- Daewon Pharm
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW-4421, sponsored by Daewon Pharm. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve at 48 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
DW-4421
Beyond the preview
Go deeper on NCT07364851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364851.